http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 20 Aug 2026 07:01:25 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Aclarion+adds+University+of+Arizona+to+CLARITY+trial+network/26952651.html <p>Aclarion, Inc. (Nasdaq: ACON, ACONW) has added the University of Arizona College of Medicine – Phoenix as a clinical site in its CLARITY trial, bringing the total number of actively enrolling sites to ten, according to a company press release.</p><p>The CLARITY trial is a 300-patient, prospective, randomized, multi-center study evaluating Aclarion's Nociscan platform in patients undergoing surgical treatment for discogenic low back pain. The primary endpoint is change in back pain measured on a 100mm visual analog scale at 12 months compared to baseline. The company anticipates an initial internal data readout and public disclosure of early interim results in http://www.streetinsider.com/Corporate+News/Aclarion+adds+University+of+Arizona+to+CLARITY+trial+network/26952651.html Thu, 20 Aug 2026 07:01:25 -0400 ACON ACONW http://www.streetinsider.com/Corporate+News/Aclarion+adds+University+of+Arizona+to+CLARITY+trial+network/26952651.html <p>Aclarion, Inc. (Nasdaq: ACON, ACONW) has added the University of Arizona College of Medicine – Phoenix as a clinical site in its CLARITY trial, bringing the total number of actively enrolling sites to ten, according to a company press release.</p><p>The CLARITY trial is a 300-patient, prospective, randomized, multi-center study evaluating Aclarion's Nociscan platform in patients undergoing surgical treatment for discogenic low back pain. The primary endpoint is change in back pain measured on a 100mm visual analog scale at 12 months compared to baseline. The company anticipates an initial internal data readout and public disclosure of early interim results in http://www.streetinsider.com/Corporate+News/Aclarion+adds+University+of+Arizona+to+CLARITY+trial+network/26952651.html Thu, 20 Aug 2026 07:01:25 -0400 ACON ACONW http://www.streetinsider.com/Press+Releases/Aclarion+Announces+Addition+of+University+of+Arizona+College+of+Medicine+%E2%80%93+Phoenix+as+CLARITY+Trial+Site/26952621.html <ul><li><strong><em>University of Arizona College of Medicine – Phoenix is home to a leading neurosurgery and orthopedic spine program with deep expertise in complex spine surgery and a strong commitment to clinical research and innovation</em></strong></li><li><strong><em>Ten sites now actively enrolling in CLARITY study, a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain </em></strong></li><li><strong><em>Nociscan® aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI)</em></strong><br></br></li></ul> <p align="justify">BROOMFIELD, Colo., Aug. 20, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MlqsTK8HOphM9qUrlaSZrDSPQrcwFjEVtchkbyeNVxr4M9OcvD8D018X2NyeutepAVPppj3yeh4SbitZOTv0tw==" rel="nofollow" target="_blank">Aclarion, Inc</a>., http://www.streetinsider.com/Press+Releases/Aclarion+Announces+Addition+of+University+of+Arizona+College+of+Medicine+%E2%80%93+Phoenix+as+CLARITY+Trial+Site/26952621.html Thu, 20 Aug 2026 07:00:00 -0400 A.07784124 A.08435063 ACON ACONW O.00073229 O.20032280 O.54253988 http://www.streetinsider.com/Press+Releases/Aclarion+Announces+Addition+of+University+of+Arizona+College+of+Medicine+%E2%80%93+Phoenix+as+CLARITY+Trial+Site/26952621.html <ul><li><strong><em>University of Arizona College of Medicine – Phoenix is home to a leading neurosurgery and orthopedic spine program with deep expertise in complex spine surgery and a strong commitment to clinical research and innovation</em></strong></li><li><strong><em>Ten sites now actively enrolling in CLARITY study, a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain </em></strong></li><li><strong><em>Nociscan® aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI)</em></strong><br></br></li></ul> <p align="justify">BROOMFIELD, Colo., Aug. 20, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MlqsTK8HOphM9qUrlaSZrDSPQrcwFjEVtchkbyeNVxr4M9OcvD8D018X2NyeutepAVPppj3yeh4SbitZOTv0tw==" rel="nofollow" target="_blank">Aclarion, Inc</a>., http://www.streetinsider.com/Press+Releases/Aclarion+Announces+Addition+of+University+of+Arizona+College+of+Medicine+%E2%80%93+Phoenix+as+CLARITY+Trial+Site/26952621.html Thu, 20 Aug 2026 07:00:00 -0400 A.07784124 A.08435063 ACON ACONW O.00073229 O.20032280 O.54253988 http://www.streetinsider.com/Press+Releases/Aclarion+Announces+Addition+of+University+of+Arizona+College+of+Medicine+%E2%80%93+Phoenix+as+CLARITY+Trial+Site/26952621.html <ul><li><strong><em>University of Arizona College of Medicine – Phoenix is home to a leading neurosurgery and orthopedic spine program with deep expertise in complex spine surgery and a strong commitment to clinical research and innovation</em></strong></li><li><strong><em>Ten sites now actively enrolling in CLARITY study, a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain </em></strong></li><li><strong><em>Nociscan® aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI)</em></strong><br></br></li></ul> <p align="justify">BROOMFIELD, Colo., Aug. 20, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MlqsTK8HOphM9qUrlaSZrDSPQrcwFjEVtchkbyeNVxr4M9OcvD8D018X2NyeutepAVPppj3yeh4SbitZOTv0tw==" rel="nofollow" target="_blank">Aclarion, Inc</a>., http://www.streetinsider.com/Press+Releases/Aclarion+Announces+Addition+of+University+of+Arizona+College+of+Medicine+%E2%80%93+Phoenix+as+CLARITY+Trial+Site/26952621.html Thu, 20 Aug 2026 07:00:00 -0400 A.07784124 A.08435063 ACON ACONW O.00073229 O.20032280 O.54253988 http://www.streetinsider.com/Press+Releases/Aclarion+Announces+Addition+of+University+of+Arizona+College+of+Medicine+%E2%80%93+Phoenix+as+CLARITY+Trial+Site/26952621.html <ul><li><strong><em>University of Arizona College of Medicine – Phoenix is home to a leading neurosurgery and orthopedic spine program with deep expertise in complex spine surgery and a strong commitment to clinical research and innovation</em></strong></li><li><strong><em>Ten sites now actively enrolling in CLARITY study, a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain </em></strong></li><li><strong><em>Nociscan® aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI)</em></strong><br></br></li></ul> <p align="justify">BROOMFIELD, Colo., Aug. 20, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MlqsTK8HOphM9qUrlaSZrDSPQrcwFjEVtchkbyeNVxr4M9OcvD8D018X2NyeutepAVPppj3yeh4SbitZOTv0tw==" rel="nofollow" target="_blank">Aclarion, Inc</a>., http://www.streetinsider.com/Press+Releases/Aclarion+Announces+Addition+of+University+of+Arizona+College+of+Medicine+%E2%80%93+Phoenix+as+CLARITY+Trial+Site/26952621.html Thu, 20 Aug 2026 07:00:00 -0400 A.07784124 A.08435063 ACON ACONW O.00073229 O.20032280 O.54253988 http://www.streetinsider.com/Press+Releases/Aclarion+Announces+Addition+of+University+of+Arizona+College+of+Medicine+%E2%80%93+Phoenix+as+CLARITY+Trial+Site/26952621.html <ul><li><strong><em>University of Arizona College of Medicine – Phoenix is home to a leading neurosurgery and orthopedic spine program with deep expertise in complex spine surgery and a strong commitment to clinical research and innovation</em></strong></li><li><strong><em>Ten sites now actively enrolling in CLARITY study, a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain </em></strong></li><li><strong><em>Nociscan® aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI)</em></strong><br></br></li></ul> <p align="justify">BROOMFIELD, Colo., Aug. 20, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MlqsTK8HOphM9qUrlaSZrDSPQrcwFjEVtchkbyeNVxr4M9OcvD8D018X2NyeutepAVPppj3yeh4SbitZOTv0tw==" rel="nofollow" target="_blank">Aclarion, Inc</a>., http://www.streetinsider.com/Press+Releases/Aclarion+Announces+Addition+of+University+of+Arizona+College+of+Medicine+%E2%80%93+Phoenix+as+CLARITY+Trial+Site/26952621.html Thu, 20 Aug 2026 07:00:00 -0400 A.07784124 A.08435063 ACON ACONW O.00073229 O.20032280 O.54253988 http://www.streetinsider.com/Press+Releases/Aclarion+Announces+Addition+of+University+of+Arizona+College+of+Medicine+%E2%80%93+Phoenix+as+CLARITY+Trial+Site/26952621.html <ul><li><strong><em>University of Arizona College of Medicine – Phoenix is home to a leading neurosurgery and orthopedic spine program with deep expertise in complex spine surgery and a strong commitment to clinical research and innovation</em></strong></li><li><strong><em>Ten sites now actively enrolling in CLARITY study, a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain </em></strong></li><li><strong><em>Nociscan® aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI)</em></strong><br></br></li></ul> <p align="justify">BROOMFIELD, Colo., Aug. 20, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MlqsTK8HOphM9qUrlaSZrDSPQrcwFjEVtchkbyeNVxr4M9OcvD8D018X2NyeutepAVPppj3yeh4SbitZOTv0tw==" rel="nofollow" target="_blank">Aclarion, Inc</a>., http://www.streetinsider.com/Press+Releases/Aclarion+Announces+Addition+of+University+of+Arizona+College+of+Medicine+%E2%80%93+Phoenix+as+CLARITY+Trial+Site/26952621.html Thu, 20 Aug 2026 07:00:00 -0400 A.07784124 A.08435063 ACON ACONW O.00073229 O.20032280 O.54253988 http://www.streetinsider.com/Press+Releases/Aclarion+Announces+Addition+of+University+of+Arizona+College+of+Medicine+%E2%80%93+Phoenix+as+CLARITY+Trial+Site/26952621.html <ul><li><strong><em>University of Arizona College of Medicine – Phoenix is home to a leading neurosurgery and orthopedic spine program with deep expertise in complex spine surgery and a strong commitment to clinical research and innovation</em></strong></li><li><strong><em>Ten sites now actively enrolling in CLARITY study, a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain </em></strong></li><li><strong><em>Nociscan® aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI)</em></strong><br></br></li></ul> <p align="justify">BROOMFIELD, Colo., Aug. 20, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MlqsTK8HOphM9qUrlaSZrDSPQrcwFjEVtchkbyeNVxr4M9OcvD8D018X2NyeutepAVPppj3yeh4SbitZOTv0tw==" rel="nofollow" target="_blank">Aclarion, Inc</a>., http://www.streetinsider.com/Press+Releases/Aclarion+Announces+Addition+of+University+of+Arizona+College+of+Medicine+%E2%80%93+Phoenix+as+CLARITY+Trial+Site/26952621.html Thu, 20 Aug 2026 07:00:00 -0400 A.07784124 A.08435063 ACON ACONW O.00073229 O.20032280 O.54253988 http://www.streetinsider.com/Globe+Newswire/Aclarion+Announces+Addition+of+University+of+Arizona+College+of+Medicine+%E2%80%93+Phoenix+as+CLARITY+Trial+Site/26952621.html <ul><li><strong><em>University of Arizona College of Medicine – Phoenix is home to a leading neurosurgery and orthopedic spine program with deep expertise in complex spine surgery and a strong commitment to clinical research and innovation</em></strong></li><li><strong><em>Ten sites now actively enrolling in CLARITY study, a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain </em></strong></li><li><strong><em>Nociscan® aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI)</em></strong><br></br></li></ul> <p align="justify">BROOMFIELD, Colo., Aug. 20, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MlqsTK8HOphM9qUrlaSZrDSPQrcwFjEVtchkbyeNVxr4M9OcvD8D018X2NyeutepAVPppj3yeh4SbitZOTv0tw==" rel="nofollow" target="_blank">Aclarion, Inc</a>., http://www.streetinsider.com/Globe+Newswire/Aclarion+Announces+Addition+of+University+of+Arizona+College+of+Medicine+%E2%80%93+Phoenix+as+CLARITY+Trial+Site/26952621.html Thu, 20 Aug 2026 07:00:00 -0400 A.07784124 A.08435063 ACON ACONW O.00073229 O.20032280 O.54253988 http://www.streetinsider.com/Globe+Newswire/Aclarion+Announces+Addition+of+University+of+Arizona+College+of+Medicine+%E2%80%93+Phoenix+as+CLARITY+Trial+Site/26952621.html <ul><li><strong><em>University of Arizona College of Medicine – Phoenix is home to a leading neurosurgery and orthopedic spine program with deep expertise in complex spine surgery and a strong commitment to clinical research and innovation</em></strong></li><li><strong><em>Ten sites now actively enrolling in CLARITY study, a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain </em></strong></li><li><strong><em>Nociscan® aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI)</em></strong><br></br></li></ul> <p align="justify">BROOMFIELD, Colo., Aug. 20, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MlqsTK8HOphM9qUrlaSZrDSPQrcwFjEVtchkbyeNVxr4M9OcvD8D018X2NyeutepAVPppj3yeh4SbitZOTv0tw==" rel="nofollow" target="_blank">Aclarion, Inc</a>., http://www.streetinsider.com/Globe+Newswire/Aclarion+Announces+Addition+of+University+of+Arizona+College+of+Medicine+%E2%80%93+Phoenix+as+CLARITY+Trial+Site/26952621.html Thu, 20 Aug 2026 07:00:00 -0400 A.07784124 A.08435063 ACON ACONW O.00073229 O.20032280 O.54253988 http://www.streetinsider.com/Globe+Newswire/Aclarion+Announces+Addition+of+University+of+Arizona+College+of+Medicine+%E2%80%93+Phoenix+as+CLARITY+Trial+Site/26952621.html <ul><li><strong><em>University of Arizona College of Medicine – Phoenix is home to a leading neurosurgery and orthopedic spine program with deep expertise in complex spine surgery and a strong commitment to clinical research and innovation</em></strong></li><li><strong><em>Ten sites now actively enrolling in CLARITY study, a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain </em></strong></li><li><strong><em>Nociscan® aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI)</em></strong><br></br></li></ul> <p align="justify">BROOMFIELD, Colo., Aug. 20, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MlqsTK8HOphM9qUrlaSZrDSPQrcwFjEVtchkbyeNVxr4M9OcvD8D018X2NyeutepAVPppj3yeh4SbitZOTv0tw==" rel="nofollow" target="_blank">Aclarion, Inc</a>., http://www.streetinsider.com/Globe+Newswire/Aclarion+Announces+Addition+of+University+of+Arizona+College+of+Medicine+%E2%80%93+Phoenix+as+CLARITY+Trial+Site/26952621.html Thu, 20 Aug 2026 07:00:00 -0400 A.07784124 A.08435063 ACON ACONW O.00073229 O.20032280 O.54253988 http://www.streetinsider.com/Globe+Newswire/Aclarion+Announces+Addition+of+University+of+Arizona+College+of+Medicine+%E2%80%93+Phoenix+as+CLARITY+Trial+Site/26952621.html <ul><li><strong><em>University of Arizona College of Medicine – Phoenix is home to a leading neurosurgery and orthopedic spine program with deep expertise in complex spine surgery and a strong commitment to clinical research and innovation</em></strong></li><li><strong><em>Ten sites now actively enrolling in CLARITY study, a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain </em></strong></li><li><strong><em>Nociscan® aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI)</em></strong><br></br></li></ul> <p align="justify">BROOMFIELD, Colo., Aug. 20, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MlqsTK8HOphM9qUrlaSZrDSPQrcwFjEVtchkbyeNVxr4M9OcvD8D018X2NyeutepAVPppj3yeh4SbitZOTv0tw==" rel="nofollow" target="_blank">Aclarion, Inc</a>., http://www.streetinsider.com/Globe+Newswire/Aclarion+Announces+Addition+of+University+of+Arizona+College+of+Medicine+%E2%80%93+Phoenix+as+CLARITY+Trial+Site/26952621.html Thu, 20 Aug 2026 07:00:00 -0400 A.07784124 A.08435063 ACON ACONW O.00073229 O.20032280 O.54253988 http://www.streetinsider.com/Globe+Newswire/Aclarion+Announces+Addition+of+University+of+Arizona+College+of+Medicine+%E2%80%93+Phoenix+as+CLARITY+Trial+Site/26952621.html <ul><li><strong><em>University of Arizona College of Medicine – Phoenix is home to a leading neurosurgery and orthopedic spine program with deep expertise in complex spine surgery and a strong commitment to clinical research and innovation</em></strong></li><li><strong><em>Ten sites now actively enrolling in CLARITY study, a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain </em></strong></li><li><strong><em>Nociscan® aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI)</em></strong><br></br></li></ul> <p align="justify">BROOMFIELD, Colo., Aug. 20, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MlqsTK8HOphM9qUrlaSZrDSPQrcwFjEVtchkbyeNVxr4M9OcvD8D018X2NyeutepAVPppj3yeh4SbitZOTv0tw==" rel="nofollow" target="_blank">Aclarion, Inc</a>., http://www.streetinsider.com/Globe+Newswire/Aclarion+Announces+Addition+of+University+of+Arizona+College+of+Medicine+%E2%80%93+Phoenix+as+CLARITY+Trial+Site/26952621.html Thu, 20 Aug 2026 07:00:00 -0400 A.07784124 A.08435063 ACON ACONW O.00073229 O.20032280 O.54253988 http://www.streetinsider.com/Globe+Newswire/Aclarion+Announces+Addition+of+University+of+Arizona+College+of+Medicine+%E2%80%93+Phoenix+as+CLARITY+Trial+Site/26952621.html <ul><li><strong><em>University of Arizona College of Medicine – Phoenix is home to a leading neurosurgery and orthopedic spine program with deep expertise in complex spine surgery and a strong commitment to clinical research and innovation</em></strong></li><li><strong><em>Ten sites now actively enrolling in CLARITY study, a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain </em></strong></li><li><strong><em>Nociscan® aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI)</em></strong><br></br></li></ul> <p align="justify">BROOMFIELD, Colo., Aug. 20, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MlqsTK8HOphM9qUrlaSZrDSPQrcwFjEVtchkbyeNVxr4M9OcvD8D018X2NyeutepAVPppj3yeh4SbitZOTv0tw==" rel="nofollow" target="_blank">Aclarion, Inc</a>., http://www.streetinsider.com/Globe+Newswire/Aclarion+Announces+Addition+of+University+of+Arizona+College+of+Medicine+%E2%80%93+Phoenix+as+CLARITY+Trial+Site/26952621.html Thu, 20 Aug 2026 07:00:00 -0400 A.07784124 A.08435063 ACON ACONW O.00073229 O.20032280 O.54253988 http://www.streetinsider.com/Globe+Newswire/Aclarion+Announces+Addition+of+University+of+Arizona+College+of+Medicine+%E2%80%93+Phoenix+as+CLARITY+Trial+Site/26952621.html <ul><li><strong><em>University of Arizona College of Medicine – Phoenix is home to a leading neurosurgery and orthopedic spine program with deep expertise in complex spine surgery and a strong commitment to clinical research and innovation</em></strong></li><li><strong><em>Ten sites now actively enrolling in CLARITY study, a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain </em></strong></li><li><strong><em>Nociscan® aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI)</em></strong><br></br></li></ul> <p align="justify">BROOMFIELD, Colo., Aug. 20, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MlqsTK8HOphM9qUrlaSZrDSPQrcwFjEVtchkbyeNVxr4M9OcvD8D018X2NyeutepAVPppj3yeh4SbitZOTv0tw==" rel="nofollow" target="_blank">Aclarion, Inc</a>., http://www.streetinsider.com/Globe+Newswire/Aclarion+Announces+Addition+of+University+of+Arizona+College+of+Medicine+%E2%80%93+Phoenix+as+CLARITY+Trial+Site/26952621.html Thu, 20 Aug 2026 07:00:00 -0400 A.07784124 A.08435063 ACON ACONW O.00073229 O.20032280 O.54253988 http://www.streetinsider.com/Corporate+News/Aclarion+receives+patent+notice+for+MRS+scan+positioning+method/26908720.html <p>Aclarion, Inc. (Nasdaq: ACON, ACONW) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application titled "Multi-Voxel Prescription for Lumbar Disc Evaluation," according to a company press release dated Aug. 12, 2026.</p> <p>The patent covers methods and systems for precisely positioning MR Spectroscopy sampling locations within lumbar discs during scan setup. The technology is designed to display both planned and shifted voxel locations during scan prescription, reducing trial-and-error in voxel positioning and lowering the likelihood of repeat scans due to suboptimal placement.</p> <p>The patent addresses a technical challenge in MRS-based disc evaluation: different chemical http://www.streetinsider.com/Corporate+News/Aclarion+receives+patent+notice+for+MRS+scan+positioning+method/26908720.html Wed, 12 Aug 2026 07:00:53 -0400 ACON ACONW O.54253988 http://www.streetinsider.com/Corporate+News/Aclarion+receives+patent+notice+for+MRS+scan+positioning+method/26908720.html <p>Aclarion, Inc. (Nasdaq: ACON, ACONW) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application titled "Multi-Voxel Prescription for Lumbar Disc Evaluation," according to a company press release dated Aug. 12, 2026.</p> <p>The patent covers methods and systems for precisely positioning MR Spectroscopy sampling locations within lumbar discs during scan setup. The technology is designed to display both planned and shifted voxel locations during scan prescription, reducing trial-and-error in voxel positioning and lowering the likelihood of repeat scans due to suboptimal placement.</p> <p>The patent addresses a technical challenge in MRS-based disc evaluation: different chemical http://www.streetinsider.com/Corporate+News/Aclarion+receives+patent+notice+for+MRS+scan+positioning+method/26908720.html Wed, 12 Aug 2026 07:00:53 -0400 ACON ACONW O.54253988 http://www.streetinsider.com/Corporate+News/Aclarion+receives+patent+notice+for+MRS+scan+positioning+method/26908720.html <p>Aclarion, Inc. (Nasdaq: ACON, ACONW) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application titled "Multi-Voxel Prescription for Lumbar Disc Evaluation," according to a company press release dated Aug. 12, 2026.</p> <p>The patent covers methods and systems for precisely positioning MR Spectroscopy sampling locations within lumbar discs during scan setup. The technology is designed to display both planned and shifted voxel locations during scan prescription, reducing trial-and-error in voxel positioning and lowering the likelihood of repeat scans due to suboptimal placement.</p> <p>The patent addresses a technical challenge in MRS-based disc evaluation: different chemical http://www.streetinsider.com/Corporate+News/Aclarion+receives+patent+notice+for+MRS+scan+positioning+method/26908720.html Wed, 12 Aug 2026 07:00:53 -0400 ACON ACONW O.54253988 http://www.streetinsider.com/Press+Releases/Aclarion+Receives+Notice+of+Allowance+for+Patent+Advancing+Accuracy+and+Adoption+of+Nociscan%26apos%3Bs+MR+Spectroscopy+%28MRS%29+Scan+Process/26908692.html <ul type="disc"><li style="margin-top:5pt; margin-bottom:5pt;"><strong><em>Patent protects the precision of MRS data capture within the target disc — a critical step in the Nociscan workflow</em></strong></li><li style="margin-top:5pt; margin-bottom:5pt;"><strong><em>Designed to reduce scan time, support faster technologist onboarding and deliver more reproducible results across imaging centers</em></strong></li><li style="margin-top:5pt; margin-bottom:5pt;"><strong><em>Extends Aclarion&apos;s IP protection to over 65 issued and pending patents worldwide, complementing its broader portfolio covering spectroscopy acquisition, data processing, biomarkers and analytics</em></strong><br/><br/></li></ul> <p align="justify">BROOMFIELD, Colo., Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=nGzaD2OGTGmSfZ9318AbxO_fbUHu9nN-Oq4DpzNgt-YRIalwrgchgX0xqjPmo72JRyaSekzUCPzYLmp5frOz9w==" rel="nofollow" target="_blank">Aclarion, Inc</a>., <strong>(“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), </strong>a commercial-stage healthcare technology company leveraging biomarkers and proprietary http://www.streetinsider.com/Press+Releases/Aclarion+Receives+Notice+of+Allowance+for+Patent+Advancing+Accuracy+and+Adoption+of+Nociscan%26apos%3Bs+MR+Spectroscopy+%28MRS%29+Scan+Process/26908692.html Wed, 12 Aug 2026 07:00:00 -0400 ACON ACONW O.54253988 http://www.streetinsider.com/Press+Releases/Aclarion+Receives+Notice+of+Allowance+for+Patent+Advancing+Accuracy+and+Adoption+of+Nociscan%26apos%3Bs+MR+Spectroscopy+%28MRS%29+Scan+Process/26908692.html <ul type="disc"><li style="margin-top:5pt; margin-bottom:5pt;"><strong><em>Patent protects the precision of MRS data capture within the target disc — a critical step in the Nociscan workflow</em></strong></li><li style="margin-top:5pt; margin-bottom:5pt;"><strong><em>Designed to reduce scan time, support faster technologist onboarding and deliver more reproducible results across imaging centers</em></strong></li><li style="margin-top:5pt; margin-bottom:5pt;"><strong><em>Extends Aclarion&apos;s IP protection to over 65 issued and pending patents worldwide, complementing its broader portfolio covering spectroscopy acquisition, data processing, biomarkers and analytics</em></strong><br/><br/></li></ul> <p align="justify">BROOMFIELD, Colo., Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=nGzaD2OGTGmSfZ9318AbxO_fbUHu9nN-Oq4DpzNgt-YRIalwrgchgX0xqjPmo72JRyaSekzUCPzYLmp5frOz9w==" rel="nofollow" target="_blank">Aclarion, Inc</a>., <strong>(“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), </strong>a commercial-stage healthcare technology company leveraging biomarkers and proprietary http://www.streetinsider.com/Press+Releases/Aclarion+Receives+Notice+of+Allowance+for+Patent+Advancing+Accuracy+and+Adoption+of+Nociscan%26apos%3Bs+MR+Spectroscopy+%28MRS%29+Scan+Process/26908692.html Wed, 12 Aug 2026 07:00:00 -0400 ACON ACONW O.54253988 http://www.streetinsider.com/Press+Releases/Aclarion+Receives+Notice+of+Allowance+for+Patent+Advancing+Accuracy+and+Adoption+of+Nociscan%26apos%3Bs+MR+Spectroscopy+%28MRS%29+Scan+Process/26908692.html <ul type="disc"><li style="margin-top:5pt; margin-bottom:5pt;"><strong><em>Patent protects the precision of MRS data capture within the target disc — a critical step in the Nociscan workflow</em></strong></li><li style="margin-top:5pt; margin-bottom:5pt;"><strong><em>Designed to reduce scan time, support faster technologist onboarding and deliver more reproducible results across imaging centers</em></strong></li><li style="margin-top:5pt; margin-bottom:5pt;"><strong><em>Extends Aclarion&apos;s IP protection to over 65 issued and pending patents worldwide, complementing its broader portfolio covering spectroscopy acquisition, data processing, biomarkers and analytics</em></strong><br/><br/></li></ul> <p align="justify">BROOMFIELD, Colo., Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=nGzaD2OGTGmSfZ9318AbxO_fbUHu9nN-Oq4DpzNgt-YRIalwrgchgX0xqjPmo72JRyaSekzUCPzYLmp5frOz9w==" rel="nofollow" target="_blank">Aclarion, Inc</a>., <strong>(“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), </strong>a commercial-stage healthcare technology company leveraging biomarkers and proprietary http://www.streetinsider.com/Press+Releases/Aclarion+Receives+Notice+of+Allowance+for+Patent+Advancing+Accuracy+and+Adoption+of+Nociscan%26apos%3Bs+MR+Spectroscopy+%28MRS%29+Scan+Process/26908692.html Wed, 12 Aug 2026 07:00:00 -0400 ACON ACONW O.54253988 http://www.streetinsider.com/Globe+Newswire/Aclarion+Receives+Notice+of+Allowance+for+Patent+Advancing+Accuracy+and+Adoption+of+Nociscan%26apos%3Bs+MR+Spectroscopy+%28MRS%29+Scan+Process/26908692.html <ul type="disc"><li style="margin-top:5pt; margin-bottom:5pt;"><strong><em>Patent protects the precision of MRS data capture within the target disc — a critical step in the Nociscan workflow</em></strong></li><li style="margin-top:5pt; margin-bottom:5pt;"><strong><em>Designed to reduce scan time, support faster technologist onboarding and deliver more reproducible results across imaging centers</em></strong></li><li style="margin-top:5pt; margin-bottom:5pt;"><strong><em>Extends Aclarion&apos;s IP protection to over 65 issued and pending patents worldwide, complementing its broader portfolio covering spectroscopy acquisition, data processing, biomarkers and analytics</em></strong><br/><br/></li></ul> <p align="justify">BROOMFIELD, Colo., Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=nGzaD2OGTGmSfZ9318AbxO_fbUHu9nN-Oq4DpzNgt-YRIalwrgchgX0xqjPmo72JRyaSekzUCPzYLmp5frOz9w==" rel="nofollow" target="_blank">Aclarion, Inc</a>., <strong>(“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), </strong>a commercial-stage healthcare technology company leveraging biomarkers and proprietary http://www.streetinsider.com/Globe+Newswire/Aclarion+Receives+Notice+of+Allowance+for+Patent+Advancing+Accuracy+and+Adoption+of+Nociscan%26apos%3Bs+MR+Spectroscopy+%28MRS%29+Scan+Process/26908692.html Wed, 12 Aug 2026 07:00:00 -0400 ACON ACONW O.54253988 http://www.streetinsider.com/Globe+Newswire/Aclarion+Receives+Notice+of+Allowance+for+Patent+Advancing+Accuracy+and+Adoption+of+Nociscan%26apos%3Bs+MR+Spectroscopy+%28MRS%29+Scan+Process/26908692.html <ul type="disc"><li style="margin-top:5pt; margin-bottom:5pt;"><strong><em>Patent protects the precision of MRS data capture within the target disc — a critical step in the Nociscan workflow</em></strong></li><li style="margin-top:5pt; margin-bottom:5pt;"><strong><em>Designed to reduce scan time, support faster technologist onboarding and deliver more reproducible results across imaging centers</em></strong></li><li style="margin-top:5pt; margin-bottom:5pt;"><strong><em>Extends Aclarion&apos;s IP protection to over 65 issued and pending patents worldwide, complementing its broader portfolio covering spectroscopy acquisition, data processing, biomarkers and analytics</em></strong><br/><br/></li></ul> <p align="justify">BROOMFIELD, Colo., Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=nGzaD2OGTGmSfZ9318AbxO_fbUHu9nN-Oq4DpzNgt-YRIalwrgchgX0xqjPmo72JRyaSekzUCPzYLmp5frOz9w==" rel="nofollow" target="_blank">Aclarion, Inc</a>., <strong>(“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), </strong>a commercial-stage healthcare technology company leveraging biomarkers and proprietary http://www.streetinsider.com/Globe+Newswire/Aclarion+Receives+Notice+of+Allowance+for+Patent+Advancing+Accuracy+and+Adoption+of+Nociscan%26apos%3Bs+MR+Spectroscopy+%28MRS%29+Scan+Process/26908692.html Wed, 12 Aug 2026 07:00:00 -0400 ACON ACONW O.54253988 http://www.streetinsider.com/Globe+Newswire/Aclarion+Receives+Notice+of+Allowance+for+Patent+Advancing+Accuracy+and+Adoption+of+Nociscan%26apos%3Bs+MR+Spectroscopy+%28MRS%29+Scan+Process/26908692.html <ul type="disc"><li style="margin-top:5pt; margin-bottom:5pt;"><strong><em>Patent protects the precision of MRS data capture within the target disc — a critical step in the Nociscan workflow</em></strong></li><li style="margin-top:5pt; margin-bottom:5pt;"><strong><em>Designed to reduce scan time, support faster technologist onboarding and deliver more reproducible results across imaging centers</em></strong></li><li style="margin-top:5pt; margin-bottom:5pt;"><strong><em>Extends Aclarion&apos;s IP protection to over 65 issued and pending patents worldwide, complementing its broader portfolio covering spectroscopy acquisition, data processing, biomarkers and analytics</em></strong><br/><br/></li></ul> <p align="justify">BROOMFIELD, Colo., Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=nGzaD2OGTGmSfZ9318AbxO_fbUHu9nN-Oq4DpzNgt-YRIalwrgchgX0xqjPmo72JRyaSekzUCPzYLmp5frOz9w==" rel="nofollow" target="_blank">Aclarion, Inc</a>., <strong>(“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), </strong>a commercial-stage healthcare technology company leveraging biomarkers and proprietary http://www.streetinsider.com/Globe+Newswire/Aclarion+Receives+Notice+of+Allowance+for+Patent+Advancing+Accuracy+and+Adoption+of+Nociscan%26apos%3Bs+MR+Spectroscopy+%28MRS%29+Scan+Process/26908692.html Wed, 12 Aug 2026 07:00:00 -0400 ACON ACONW O.54253988